Tempest Registers 8.9M Shares for Lincoln Park Equity Line — Up to $50M in Dilutive Financing

summarizeSummary

Tempest Therapeutics registered 8.9 million shares for a $50 million equity line with Lincoln Park, providing critical liquidity but at the cost of significant dilution to existing shareholders.

check_boxKey Events · Financing and Capital Events · TPST

• Equity Line Registration

  S-1 registers 8,910,579 shares for resale by Lincoln Park, including 560,356 commitment shares already issued and up to 8 million shares to be sold at Tempest's discretion.

• Financing Terms

  Purchase price set at 97% of the lower of the lowest sale price on the purchase date or the average of three lowest closing prices over the prior 10 days; maximum $500,000 per regular purchase.

• Dilution Impact

  If all 8 million shares are sold, they would represent approximately 33% of current outstanding shares, with gross proceeds of about $8.2 million at the current $1.02 price.

• Exchange Cap Limitation

  Issuances capped at 3,195,881 shares (19.99% of outstanding) unless stockholder approval is obtained or the average sale price exceeds $1.3854 per share.

auto_awesomeAnalysis · TPST · Life Sciences

Tempest Therapeutics filed an S-1 to register 8,910,579 shares for resale by Lincoln Park Capital under a $50 million equity line of credit. The company can sell up to 8 million shares at a 3% discount to market, with proceeds potentially reaching $8.2 million at the current $1.02 price. This financing is critical given the company's going concern warning and only $0.8 million in cash as of Q2 2026, but it comes with substantial dilution — the registered shares represent about 33% of current outstanding shares. The deal includes an Exchange Cap of 19.99% of outstanding shares, requiring stockholder approval for further issuances unless the average price exceeds $1.3854. The pricing formula and discount structure are typical for equity lines but reflect the company's distressed position and limited financing options.